Form 8-K - Current report:
SEC Accession No. 0001213900-24-113467
Filing Date
2024-12-30
Accepted
2024-12-30 16:00:33
Documents
13
Period of Report
2024-12-23
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0226291-8k_raphael.htm   iXBRL 8-K 30854
  Complete submission text file 0001213900-24-113467.txt   203368

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE raph-20241223.xsd EX-101.SCH 3054
3 XBRL LABEL FILE raph-20241223_lab.xml EX-101.LAB 34916
4 XBRL PRESENTATION FILE raph-20241223_pre.xml EX-101.PRE 22815
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0226291-8k_raphael_htm.xml XML 3385
Mailing Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108
Business Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108 702-442-1166
Raphael Pharmaceutical Inc. (Filer) CIK: 0001415397 (see all company filings)

EIN.: 260204284 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-53002 | Film No.: 241589630
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)